Golidocitinib Plus CHOP in Newly Diagnosed PTCL

NCT06739265 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T-cell Lymphoma

Interventions

DRUG: Golidocitinib plus CHOP

Sponsor

Peking Union Medical College Hospital